Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please have a quick look at this :
https://www.genfit.com/wp-content/uploads/2019/01/2019.01.08-Corporate-deck-website.pdf
Sold my 700 shares for a 20+% return awaiting the next re-entry point
Shorts are trapped again. Earnings awesome!!! Fry shorts
Added another 350!shares today. Thank you for the deal
Just loaded 350 shares. We’ll oversold here. 100 will hold strong
Is this coming alive again? Sold out of this at 120+ made huge money back in the day.
Looks like the 8K came out late Friday. I thought we'd climb right back to 70 from announcment of labeling but probably just going to yoyo 50-65...
ICPT’s partner dumps Ocaliva for Japanese/Korean markets; this was buried in ICPT’s 4Q17 PR:
https://finance.yahoo.com/news/intercept-pharmaceuticals-reports-full-fourth-120500415.html
In February, Intercept amended its exclusive license agreement with Sumitomo Dainippon to regain the rights to develop and commercialize OCA in Japan and Korea. Under the new terms of the license agreement, Intercept will forego any further milestone or royalty payments for the development and commercialization of OCA in these countries.
Please see the posts linked in #msg-137643821 and the reply chains to those posts.
The article somewhat overstates the PBC safety issues, while the larger concern for ICPT over the next few years (IMO) is the low probability of success in the phase-3 NASH trial.
The article somewhat overstates the PBC safety issues, while the larger concern for ICPT over the next few years (IMO) is the low probability of success in the phase-3 NASH trial.
I like to see opposing view points from this article below, and comments about ICPT's phase 3 NASH trials (Regenerate and Reverse).
https://finance.yahoo.com/news/primary-reason-intercept-pharmaceuticals-inc-153200816.html
JPM just recently filed 13G.
On Watch For Breakout In Shares Of Intercept Pharmaceuticals Inc
Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) are hammering on a breakout trend line at $62.50. Should the stock push through, it will likely surge to as high as $66.50, perhaps within a day or two. Definitely a chart investors should be watching.
Gareth Soloway
InTheMoneyStocks
Recent changes to REGENERATE trial:
https://twitter.com/DewDiligence/status/935213189863796738
ICPT hires R&D head:
https://globenewswire.com/news-release/2017/11/27/1206216/0/en/Intercept-Pharmaceuticals-Appoints-Christian-Weyer-as-Executive-Vice-President-of-Research-Development.html
How many candidates did they have to interview, LOL?
Rachel McMinn is leaving the company effective 12/31/17.
ICPT stopped development of INT-767, the backup FXR agonist. It’s presumably no better than Ocaliva.
Probably needs a couple days...
Intercept Pharmaceuticals (ICPT) Worst-Case is 'Surmountable', No Change to Outlook - Baird - Intercept Pharmaceuticals (ICPT) Worst-Case is 'Surmountable', No Change to Outlook - Baird - https://www.streetinsider.com/dr/news.php?id=13324895&gfv=1
ICPT attempt at damage control fails to lift stock: #msg-134886802.
We cannot be happy when at least 26 persons died because of OCA.
I hope you have listened my advices and you have not lost too much money .
There is only one safety candidate in phase 3, it s time that USA stops
Its protectionism. Genfit is number 1 and safe!
Well osaffer you got your wish I hope it makes you happy!
OCA seems to be not so yummy
ICPT –16% on Ocaliva safety warning: #msg-134545079.
That blogger is as bearish on ICPT as I am, LOL.
These results are awesome ...
Prurit is present for all branches of dose's OCA
Increase of LDL
14 patients have disapeared from the study
1 patient died ...
Everybody know the side effect of Statins, it means, that, most of patient using already Statins, will have to increase their doses of statins to fight the side effect of OCA LOL
Do not forget, that FDA has recommended to ICPT to reduce dose of OCA for PBC, because of side effects .
Because of side effect of statins, I guess, patient will take an other workaround ...
Small phase-2 shows adding statins to Ocaliva neutralizes LDL increase, but this is hardly surprising—nor does it make OCA a better drug for treating NASH, IMO:
#msg-133432507
It's to the point now I can't defend this stock anymore it really is a useless pile of shit and ocliva is a total bust !!
You're preaching to the choir vis-á-vis Ocaliva. I'm bearish on the REGENERATE trial, and have said so numerous times.
On the other hand, newer and better FXR agonists do not seem to have the side-effect baggage that comes with Ocaliva. I'm bullish on ENTA's NASH compound, EDP-305. (I'm long ENTA.)
Dont forget, that OCALIVA has received approbation from FDA only because there was not other treatment for PBC. And, the doses have been reduced.
Dont forget that OCALIVA increase bad cholesterol, it means, it can increase the risk of cardiovascular issue ...
Maybe you knew Georges Michaël ...
Anyway, when you have choice to take OCALIVA with all undesire effects, or Elafibranor, what would you to take ?
What would you prefer that your doctor give you ?
For me choice is fast ... It s not only a question of money, but public health ...
Risk of cancer, increase of bad cholesterol, prurit .. only attack the Fibrosis, and not the NASH, while Fibrosis is a consequence of NASH ...
Ok, you are saying not a big deal ... We ll see that ...
Not a big deal, IMO: #msg-129405710.
FXR agonist Cancer ? This is not good for ICPT, Gilead
http://www.journal-of-hepatology.eu/article/S0168-8278(17)30062-4/pdf
The CC slides have only the design outline of the REGENERATE trial—no details on p-value thresholds.
ICPT -8% on 4Q16 results: #msg-128940872.
Followers
|
44
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
625
|
Created
|
10/11/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |